BR112014011670A2 - anticorpo anti- adrenomedulina (adm) ou fragmento de anticorpo anti -adm ou uma estrutura anti- adm não-ig para utilização em terapia - Google Patents
anticorpo anti- adrenomedulina (adm) ou fragmento de anticorpo anti -adm ou uma estrutura anti- adm não-ig para utilização em terapiaInfo
- Publication number
- BR112014011670A2 BR112014011670A2 BR112014011670A BR112014011670A BR112014011670A2 BR 112014011670 A2 BR112014011670 A2 BR 112014011670A2 BR 112014011670 A BR112014011670 A BR 112014011670A BR 112014011670 A BR112014011670 A BR 112014011670A BR 112014011670 A2 BR112014011670 A2 BR 112014011670A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- adm
- fragment
- adrenomedulin
- scaffold
- Prior art date
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title abstract 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title abstract 12
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 abstract 4
- 230000000087 stabilizing effect Effects 0.000 abstract 3
- 208000030090 Acute Disease Diseases 0.000 abstract 2
- 102000004379 Adrenomedullin Human genes 0.000 abstract 2
- 101800004616 Adrenomedullin Proteins 0.000 abstract 2
- 208000017667 Chronic Disease Diseases 0.000 abstract 2
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 230000014759 maintenance of location Effects 0.000 abstract 2
- 230000003472 neutralizing effect Effects 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
Abstract
abstract subject matter of the present invention is an anti-adrenomedullin antibody or an anti-adrenomedullin antibody fragment or anti-adm non-ig scaffold wherein said antibody or said fragment or scaffold is a non-neutralizing antibody, antibody fragment or non-ig scaffold, respectively. subject matter of the present invention is also an anti-adrenomedullin antibody or an anti-adrenomedullin antibody fragment or anti-adm non-ig scaffold for use in a treatment of a chronic or acute disease wherein said antibody or fragment or scaffold is: * an adm stabilizing antibody or an adrenomedullin stabilizing antibody fragment or an adm stabilizing non-ig scaffold that enhances the t1/2 half retention time of adrenomedullin in serum, blood, plasma at least 10 %, preferably at least, 50 %, more preferably >50 %, most preferably 100 % and/or * wherein said anti-adm antibody or an anti-adrenomedullin antibody fragment or anti-adm non-ig scaffold blocks the bioactivity of adm to not more than 80 %, or not more than 50 %. tradução do resumo resumo patente de invenção: "anticorpo anti- adrenomedulina ( adm ) ou fragmento de anticorpo anti -admy ou uma estutura anti- adm não-ig para uso em terapia". a presente descrição refere-se a um anticorpo anti - adrenomedulina ou um fragmento de anticorpo anti - adrenomedulina ou uma estrutura anti - adm não- ig , em que o referido anticorpo ou o referido fragmento ou estrutura é um anticorpo não neutralizante , fragmento de anticorpo ou um estrutura não- ig , respectivamente. a presente invenção refere-se a um anticorpo anti - adrenomedulina ou um fragmento de anticorpo anti - adrenomedulina ou uma estrutura anti - adm não- ig para uso no tratamento de uma doença crônica ou aguda , em que o referido anticorpo ou fragmento ou estrutura é : um adm que estabiiza o anticorpo ou um fragmento de anticorpo que estabiiza o anticorpo ou um adm que estabiliza à estrutura não lg que aumenta a metade do tempo de retenção t1 / 2 de adrenomedulina no soro , sangue , plasma , pelo menos, 10 % , de preferência pelo menos , 50 % , mais preferencialmente > 50 % , mais de preferência de 100% e / ou em que o referido anticorpo anti - adm ou um fragmento de anticorpo anti - adrenomedulina ou uma estrutura anti - adm não-ig bloqueia a bioatividade de adm de não mais do que 80 % , ou não mais do que 50 %.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11189448.1 | 2011-11-16 | ||
| EP11189448 | 2011-11-16 | ||
| EP12160018 | 2012-03-16 | ||
| EP12160018.3 | 2012-03-16 | ||
| PCT/EP2012/072931 WO2013072512A1 (en) | 2011-11-16 | 2012-11-16 | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014011670A2 true BR112014011670A2 (pt) | 2017-05-09 |
| BR112014011670B1 BR112014011670B1 (pt) | 2021-05-25 |
Family
ID=48087103
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014011670-9A BR112014011670B1 (pt) | 2011-11-16 | 2012-11-16 | anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou um arcabouço de proteína não-igg anti-adm que se liga à adrenomedulina e formulação farmacêutica |
| BR122019027917-9A BR122019027917B1 (pt) | 2011-11-16 | 2012-11-16 | Uso de um anticorpo anti-adrenomedulina (adm) enxertado em cdr humano ou humanizado ou fragmento de anticorpo anti-adm do mesmo |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR122019027917-9A BR122019027917B1 (pt) | 2011-11-16 | 2012-11-16 | Uso de um anticorpo anti-adrenomedulina (adm) enxertado em cdr humano ou humanizado ou fragmento de anticorpo anti-adm do mesmo |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2594588B1 (pt) |
| JP (1) | JP6321545B2 (pt) |
| KR (3) | KR102047443B1 (pt) |
| CN (4) | CN104144948B (pt) |
| AU (1) | AU2012338732B2 (pt) |
| BR (2) | BR112014011670B1 (pt) |
| CA (1) | CA2856141C (pt) |
| DK (1) | DK2594588T3 (pt) |
| ES (1) | ES2494191T3 (pt) |
| HK (1) | HK1202127A1 (pt) |
| IL (2) | IL283215B2 (pt) |
| MX (1) | MX355482B (pt) |
| PL (1) | PL2594588T3 (pt) |
| PT (1) | PT2594588E (pt) |
| RU (1) | RU2662671C2 (pt) |
| SG (1) | SG11201402351WA (pt) |
| WO (1) | WO2013072512A1 (pt) |
| ZA (1) | ZA201403548B (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104144948B (zh) * | 2011-11-16 | 2021-10-15 | 艾德里诺医药公司 | 用于治疗的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig骨架 |
| BR112018010269A2 (pt) * | 2015-11-27 | 2019-02-05 | Brahms Gmbh | mr-proadm como marcador para o status do volume extracelular de um indivíduo |
| WO2018007588A1 (en) * | 2016-07-08 | 2018-01-11 | Sphingotec Gmbh | Adrenomedullin for assessing congestion in a subject with acute heart failure |
| EP3339324A1 (en) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
| CN110167962B (zh) * | 2016-12-16 | 2024-06-07 | 艾德里诺医药公司 | 用于干预和治疗需要的患者的充血的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架 |
| CN110678550B (zh) * | 2017-03-29 | 2023-11-14 | 国立大学法人宫崎大学 | 长效肾上腺髓质素衍生物 |
| BR112020005450A2 (pt) * | 2017-09-25 | 2020-09-29 | Adrenomed Ag | aglutinante antiadrenomedulina (adm) para uso em terapia ou prevenção dos sintomas de doença |
| EP3698134A1 (en) | 2017-10-18 | 2020-08-26 | AdrenoMed AG | Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder |
| MX2020008345A (es) * | 2018-02-08 | 2020-09-25 | Sphingotec Gmbh | Adrenomedulina (adm) para el diagnostico y/o prediccion de demencia y un aglutinante de anti-adrenomedulina para usarse en la terapia o prevencion de demencia. |
| CN114556100A (zh) | 2019-08-30 | 2022-05-27 | 4Teen4制药有限公司 | 用于治疗休克的疗法指引和/或疗法监测 |
| EP3871689A1 (en) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| KR20220145898A (ko) | 2020-02-27 | 2022-10-31 | 아드레노메드 아게 | 쇼크 환자의 치료에 사용하기 위한 항-아드레노메둘린 (adm) 결합제 |
| EP4111204A1 (en) | 2020-02-27 | 2023-01-04 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock |
| IL295728A (en) | 2020-02-27 | 2022-10-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm backbone without ig for use in the treatment of cure or prevention of shock |
| MX2022011577A (es) | 2020-03-16 | 2022-10-18 | Sphingotec Gmbh | Proadrenomedulina o fragmento de la misma en pacientes infectados con coronavirus y tratamientos con aglutinante contra la adrenomedulina. |
| WO2023175035A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
| TW202413415A (zh) * | 2022-07-20 | 2024-04-01 | 大陸商上海濟煜醫藥科技有限公司 | 抗腎上腺髓質素非中和抗體、其製備方法及用途 |
| WO2024023369A1 (en) | 2022-07-29 | 2024-02-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| WO2024023368A1 (en) | 2022-07-29 | 2024-02-01 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JP2774769B2 (ja) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| CA2383419A1 (en) * | 1999-09-10 | 2001-03-15 | Frank Cuttitta | Determination of am-binding proteins and the association of adrenomedullin (am) therewith |
| KR20040059490A (ko) | 2001-08-30 | 2004-07-05 | 바이오렉시스 파마슈티칼 코포레이션 | 변형 트랜스페린 융합 단백질 |
| CA2488558C (en) | 2002-06-07 | 2013-08-20 | Dyax Corp. | Prevention and reduction of blood loss |
| DE10316583A1 (de) * | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| EP1620734A1 (en) | 2003-04-25 | 2006-02-01 | Genova Ltd. | Secreted polypeptide species reduced cardiovascular disorders |
| EP1675878A2 (en) | 2003-10-24 | 2006-07-05 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| US20070280886A1 (en) | 2004-09-09 | 2007-12-06 | Bayer Healthcare Ag | Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr) |
| CA2477867A1 (en) * | 2004-09-17 | 2006-03-17 | Oncorex, Inc. | Peptides, dna's, rna's, and compounds for inhibiting or inducing adrenomedullin activity, and use of the same |
| EP2314308A1 (en) | 2004-09-21 | 2011-04-27 | BioNTech AG | Use of microproteins as tryptase inhibitors |
| WO2007062676A1 (en) | 2005-12-01 | 2007-06-07 | B.R.A.H.M.S. Aktiengesellschaft | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
| CN101165067B (zh) * | 2006-10-19 | 2011-04-20 | 四川大学华西医院 | 肾上腺髓质素(27-52)的固相合成方法 |
| ATE527353T1 (de) | 2007-12-19 | 2011-10-15 | Affibody Ab | Pdgf-bindendes polypeptid aus protein a |
| CN107011425B (zh) | 2008-11-03 | 2021-01-01 | 分子组合公司 | 抑制vegf-a受体相互作用的结合蛋白 |
| EP2470556B1 (en) | 2009-08-27 | 2018-05-30 | Covagen AG | Il-17 binding compounds and medical uses thereof |
| CA2778872C (en) | 2009-12-14 | 2015-06-02 | Scil Proteins Gmbh | A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands |
| JP5902679B2 (ja) | 2010-06-08 | 2016-04-13 | ピエリス アーゲーＰｉｅｒｉｓ Ａｇ | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン |
| CN104144948B (zh) * | 2011-11-16 | 2021-10-15 | 艾德里诺医药公司 | 用于治疗的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig骨架 |
-
2012
- 2012-11-16 CN CN201280066575.2A patent/CN104144948B/zh active Active
- 2012-11-16 CN CN202410037251.0A patent/CN118105479A/zh active Pending
- 2012-11-16 ES ES12193121.6T patent/ES2494191T3/es active Active
- 2012-11-16 KR KR1020147015835A patent/KR102047443B1/ko active IP Right Grant
- 2012-11-16 RU RU2014123990A patent/RU2662671C2/ru active
- 2012-11-16 KR KR1020197027994A patent/KR102176469B1/ko active IP Right Grant
- 2012-11-16 WO PCT/EP2012/072931 patent/WO2013072512A1/en active Application Filing
- 2012-11-16 BR BR112014011670-9A patent/BR112014011670B1/pt active IP Right Grant
- 2012-11-16 DK DK12193121.6T patent/DK2594588T3/da active
- 2012-11-16 BR BR122019027917-9A patent/BR122019027917B1/pt active IP Right Grant
- 2012-11-16 JP JP2014541696A patent/JP6321545B2/ja active Active
- 2012-11-16 KR KR1020207029323A patent/KR102249078B1/ko active IP Right Grant
- 2012-11-16 MX MX2014005996A patent/MX355482B/es active IP Right Grant
- 2012-11-16 PL PL12193121T patent/PL2594588T3/pl unknown
- 2012-11-16 CN CN202111048028.9A patent/CN114044824A/zh active Pending
- 2012-11-16 EP EP12193121.6A patent/EP2594588B1/en active Active
- 2012-11-16 IL IL283215A patent/IL283215B2/en unknown
- 2012-11-16 CN CN201811275032.7A patent/CN110054690B/zh active Active
- 2012-11-16 SG SG11201402351WA patent/SG11201402351WA/en unknown
- 2012-11-16 PT PT121931216T patent/PT2594588E/pt unknown
- 2012-11-16 AU AU2012338732A patent/AU2012338732B2/en active Active
- 2012-11-16 CA CA2856141A patent/CA2856141C/en active Active
-
2014
- 2014-05-14 IL IL232635A patent/IL232635B/en active IP Right Grant
- 2014-05-15 ZA ZA2014/03548A patent/ZA201403548B/en unknown
-
2015
- 2015-03-16 HK HK15102663.5A patent/HK1202127A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014011670A2 (pt) | anticorpo anti- adrenomedulina (adm) ou fragmento de anticorpo anti -adm ou uma estrutura anti- adm não-ig para utilização em terapia | |
| MY178654A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy | |
| CY1125144T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης | |
| CY1121203T1 (el) | Θεραπευτικες χρησεις της εμπαγλιφλοζινης | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| CY1118377T1 (el) | Syk αναστολεις ιμιδαζοπυραζινης | |
| BR112015001419A2 (pt) | composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios | |
| BR112013020798A2 (pt) | terapia de combinação do inibidor mtor /jak | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| CO6390109A2 (es) | Inhibidores de syk de imidazopirazina | |
| EA201500997A1 (ru) | Терапевтические применения эмпаглифлозина | |
| EA201301107A1 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| BR112013020620A2 (pt) | análogos de ácido 4-hidroxibutírico | |
| EA201391581A1 (ru) | Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств | |
| BR112015014034A2 (pt) | inibidores de irak e usos dos mesmos | |
| BR112015001521A2 (pt) | previsão de resposta ao tratamento para inibidor jak/stat | |
| ZA201403552B (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition | |
| BR112012023660B8 (pt) | usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| BR112014009785A8 (pt) | método para tratar ou reduzir efp | |
| BR112015022092A2 (pt) | derivado de di-hidropiridazina-3,5-diona | |
| BR112013027486A2 (pt) | combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor | |
| BR112013029182A2 (pt) | método para o tratamento de malignidades sólidas incluindo malignidades sólidas avançadas ou metastáticas | |
| BR112015020199A2 (pt) | usos terapêuticos para anticorpos de vegfr1 | |
| BR112014005538A2 (pt) | composições aquosas compreendendo arbecacina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/11/2012, OBSERVADAS AS CONDICOES LEGAIS. |